| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Development Officer | Exec VP, Program Team Lead
1 company
Eisele Jeffrey is a Chief Development Officer at Apellis Pharmaceuticals, Inc.. Recent SEC Form 4 filings include 0 buys and 12 sells.
Estimated insider holdings value: $2.3M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 29, 2025 | APLS Apellis Pharmaceuticals, Inc. | Chief Development Officer | Sell | 278 | $29.52 | $8,207.56 | -0.5% | -38.2% | -21.8% | |
| Jan 22, 2025 | APLS Apellis Pharmaceuticals, Inc. | Chief Development Officer | Sell | 1,291 | $30.43 | $39,279.32 | -2.3% | -42.8% | -27.6% | |
| Jan 13, 2025 | APLS Apellis Pharmaceuticals, Inc. | Chief Development Officer | Sell | 264 | $28.70 | $7,577.35 | -0.5% | -32.4% | -25.4% | |
| Dec 23, 2024 | APLS Apellis Pharmaceuticals, Inc. | Chief Development Officer | Sell | 63 | $33.09 | $2,084.67 | -0.1% | -26.9% | -25.3% | |
| Jan 30, 2024 | APLS Apellis Pharmaceuticals, Inc. | Chief Development Officer | Sell | 1,250 | $65.22 | $81,524.19 | -1.1% | -27.5% | -55.3% | |
| Jan 23, 2024 | APLS Apellis Pharmaceuticals, Inc. | Chief Development Officer | Sell | 7,378 | $63.69 | $469,904.82 | -11.2% | -28.0% | -54.1% | |
| Jan 22, 2024 | APLS Apellis Pharmaceuticals, Inc. | Chief Development Officer | Sell | 1,607 | $65.00 | $104,448.57 | -2.4% | -27.2% | -54.0% | |
| Jan 17, 2024 | APLS Apellis Pharmaceuticals, Inc. | Chief Development Officer | Sell | 5,207 | $65.58 | $341,475.06 | -7.2% | -21.4% | -54.9% | |
| Jan 16, 2024 | APLS Apellis Pharmaceuticals, Inc. | Chief Development Officer | Sell | 438 | $66.81 | $29,262.17 | -0.6% | -22.3% | -56.2% | |
| Dec 27, 2023 | APLS Apellis Pharmaceuticals, Inc. | Chief Development Officer | Sell | 303 | $59.70 | $18,088.59 | -0.3% | -6.3% | -47.6% |